Several studies have revealed that patients with the immune-excluded phenotype had a poor prognosis compared to patients with the inflamed or desert phenotype in various tumors because immune-excluded tumors were immunosuppressed by T-cells embedded in the tumor stromal microenvironment with upregulation of TGFβ, myeloid inflammation, and angiogenesis [10,14,39]. This evidence concerns the gene TGFB1 and neoplasm.